The Role of Telehealth and Telemedicine in Addiction Treatment (1.5 CME)
(1.5 CME) In this conference recording from the 2019 Annual Conference, you will learn:
|Telemedicine is increasingly popular as a method to deliver addiction treatment. Use of video technology allows improved access to specialized care, particularly for patients living in rural and underserved areas. Prescribing medication treatment for opioid use disorder through telemedicine is also enhancing our ability to address the opioid epidemic. However, this is an arena with rapidly changing regulation and reimbursement. During this session, we will examine factors that need to be considered when delivering telemedicine services for addiction treatment. The broader concept of telehealth encompasses a wide variety of other health related activities, such as web-based continuing professional education; electronic patient reminders, education, monitoring, and access to personal health information; and remote consultation between medical providers. The ECHO model is an increasingly popular approach that combines several features of telehealth in order to provide case-based telementoring, continuing professional education, and expansion of healthcare workforce capacity. We will also examine in this session the rapid expansion of the use of ECHO to address the opioid epidemic and other addiction medicine arenas in the US and internationally.|
|1.) Understand how telemedicine works in treatment of SUDs, and the technology and infrastructure needed in order to treat patients via telemedicine.|
|2.) Stay compliant with federal and state laws and regulations when utilizing these resources.|
|3.) Understand how participation in addiction-focused ECHO programs can enhance clinical knowledge and decision-making and expand workforce capacity to address SUDs.|
|Dr. David Kan graduated from Northwestern University Medical School. He completed his general and forensic psychiatry training at the University of California, San Francisco. The majority of Dr. Kan's career has been spent in opioid treatment. Dr. Kan was the Medical Director of San Francisco VA Medical Center Opioid Treatment Program from 2005-2015 and he is the current Medical Director of Bright Heart Health. Dr. Kan is a faculty member within the UCSF Department of Psychiatry. Dr. Kan has won several awards for excellence in teaching. In addition to his psychiatry practice, Dr. Kan consults to attorneys and courts on medical-legal matters. Dr. Kan serves on California state's State Opioid Safety Workgroup. Dr. Kan is active within ASAM. Dr. Kan is the current President of the California Society of Addiction Medicine.|
MD, FACP, DFASAM
|Dr. Miriam Komaromy is a physician and professor of medicine at the University of New Mexico in the United States. She is board certified in Internal Medicine and Addiction Medicine. She has been an Associate Director in the ECHO Institute, leading ECHO programs that are focused on treatment of substance use disorders for the past 13 years. She consults with programs around the world on implementation of the ECHO model to expand access to specialized medical care, and particularly focuses on ECHO for addictions, mental health, care of complex populations, and ECHO programs to support community health workers. Dr. Komaromy provides clinical consultation and outpatient care for patients with complex substance use disorders. She has served as Medical Director for New Mexico’s addiction treatment hospital, and led the development of the state’s guidelines for treatment of opioid use disorder. Dr. Komaromy is a member of the board of directors of the American Society of Addiction Medicine (ASAM), which is the largest addiction-specialty society in the United States. She is vice-chair of ASAM’s national medical education committee, and she chairs their Fundamentals of addiction medicine committee. She was recently elected ASAM educator of the year for 2019. Dr. Komaromy lectures nationally and internationally on addiction medicine topics, including treatment of opioid use disorder, harm reduction, and how to address the use of amphetamine-type substances. Dr. Komaromy is currently serving as a Fulbright Scholar in Hanoi, Vietnam, performing research and providing education on treatment of substance use disorders.|
Dr. Aaron D. Greenblatt, MD
Medical Director, UMMC Opioid Treatment Program, University of Maryland School of Medicine
Dr. Greenblatt has been a faculty member at the University of Maryland School of Medicine since completing his fellowship in Addiction Medicine. He divides his clinical responsibilities between the Division of Addiction Research and Treatment (DART) in the Department of Psychiatry and the Department of Family and Community Medicine. He is medical director of the University of Maryland Drug Treatment Center (DTC), where he treats patients, coordinates clinical care, hosts research projects, and participates in the clinical education of medical students, psychiatry residents, and addiction fellows. He is currently working to further the integration of medical and mental health services in the DTC. Dr. Greenblatt also provides addiction treatment via telemedicine in rural Maryland, and has published and lectured on the topic. He fields consultation requests for MACS, a statewide warmline for clinical questions about addiction. He is working on addiction treatment in the SNF setting, and provides low-threshold buprenorphine treatment in a drop-in center focusing on harm reduction for sex workers. He is also the associate director of the Addiction Medicine Fellowship at UMMC.
In the Department of Family and Community Medicine, he precepts medical students and residents in their training and assists with curriculum development, especially in domains that relate to the intersection of primary care, care of chronic illness in patients with addiction, and enhanced treatment of substance use disorders.
ACCME Accreditation Statement
The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA Credit Designation Statement
The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABPM Maintenance of Certification (MOC)
The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.
ABAM Transitional Maintenance of Certification (tMOC)
This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.
ABIM Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.